Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 6, 2009, Pages 751-758

  Xie, Qing Qing ^a   Xie, Huan Zhang ^a,b   Ren, Ji Xia ^a   Li, Lin Li ^b   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Kinase inhibitor; Pharmacophore model; Tie2; Type I kinase inhibitor; Type II kinase inhibitor

Indexed keywords

KINASE INHIBITOR; PHARMACOPHORE MODEL; TIE2; TYPE I KINASE INHIBITOR; TYPE II KINASE INHIBITOR;

AROMATIC COMPOUNDS; HYDROGEN; HYDROPHOBICITY; SOFTWARE PACKAGES;

PHARMACODYNAMICS;

ADENOSINE TRIPHOSPHATE; ANGIOPOIETIN RECEPTOR; PHOSPHOTRANSFERASE INHIBITOR;

ARTICLE; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

COMPUTER SIMULATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RECEPTOR, TIE-2;

EID: 59149084702     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.11.008     Document Type: Article

References (29)

1. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
2. Mazitschek R., and Giannis A. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Curr. Opin. Chem. Biol. 8 (2004) 432-441
3. Kim K., Li B., Winter J., Armanini M., Gillett N., Phillips H., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
4. Tigue C.C., Fitzner K.A., Alkhatib M., Schmid E., and Bennett C.L. The value of innovation: the economics of targeted drugs for cancer. Targ. Oncol. 2 (2007) 113-119
5. Madhusudan S., and Ganesan T.S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 37 (2004) 618-635
6. Bach F., Uddin F.J., and Burke D. Angiopoietins in malignancy. Eur. J. Surg. Oncol. 33 (2007) 7-15
7. Stratmann A., Acker T., Burger A.M., Amann K., Risau W., and Plate K.H. Differential inhibition of tumor angiogenesis by Tie2 and Vascular Endothelial Growth Factor Receptor-2 dominant-negative receptor mutants. Int. J. Cancer 91 (2001) 273-282
8. Stratmann A., Risau W., and Plate K.H. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153 (1998) 1459-1466
9. Wang M.P., Chan S.Y., Fu K.H., Leung S.Y., Cheung N., Yuen S.T., and Chung L.P. The angiopoietin, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29 (2000) 11-12
10. Wurmbach J.H., Hammerer P., Sevinc S., Huland H., and Ergün S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 20 (2000) 5217-5220
11. Lin P., Buxton J.A., Acheson A., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D., Channon K.M., Hale L.P., Dewhirst M.W., George S.E., and Peters K.G. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8829-8834
12. Lin P., Sankar S., Shan S., Dewhirst M.W., Polverini P.J., Quinn T.Q., and Peters K.G. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9 (1998) 49-58
13. Cee V.J., Albrecht B.K., Geuns-Meyer S., Hughes P., Bellon S., Bready J., Caenepeel S., Chaffee S.C., Coxon A., Emery M., Fretland J., Gallant P., Gu Y., Hodous B.L., Hoffman D., Johnson R.E., Kendall R., Kim J.L., Long A.M., McGowan D., Morrison M., Olivieri P.R., Patel V.F., Polverino A., Powers D., Rose P., Wang L., and Zhao H. Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J. Med. Chem. 50 (2007) 627-640
14. Hodous B.L., Geuns-Meyer S.D., Hughes P.E., Albrecht B.K., Bellon S., Bready J., Caenepeel S., Cee V.J., Chaffee S.C., Coxon A., Emery M., Fretland J., Gallant P., Gu Y., Hoffman D., Johnson R.E., Kendall R., Kim J.L., Long A.M., Morrison M., Olivieri P.R., Patel V.F., Polverino A., Rose P., Tempest P., Wang L., Whittington D.A., and Zhao H. Evolution of a highly selective and potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. J. Med. Chem. 50 (2007) 611-626
15. Semones M., Feng Y., Johnson N., Adams J.L., Winkler J., and Hansbury M. Pyridinylimidazole inhibitors of Tie2 kinase. Bioorg. Med. Chem. Lett. 17 (2007) 4756-4760
16. Liu J., Lin T.H., Cole A.G., Wen R., Zhao L., Brescia M., Jacob B., Hussain Z., Appell K.C., Henderson I., and Webb M.L. Identification and characterization of small-molecule inhibitors of Tie2 kinase. FEBS Lett. 582 (2008) 785-791
17. Dandu R., Zulli A.L., Bacon E.R., Underiner T., Robinson C., Chang H., Miknyoczki S., Grobelny J., Ruggeri B.A., Yang S., Albom M.S., Angeles T.S., Aimone L.D., and Hudkins R.L. Design and synthesis of dihydroindazolo[5,4-a] pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorg. Med. Chem. Lett. 18 (2008) 1916-1921
18. Hasegawa M., Nishigaki N., Washio Y., Kano K., Harris P.A., Sato H., Mori I., West R.I., Shibahara M., Toyoda H., Wang L., Nolte R.T., Veal J.M., and Cheung M. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J. Med. Chem. 50 (2007) 4453-4470
19. Ji Z., Ahmed A.A., Albert D.H., Bouska J.J., Bousquet P.F., Cunha G.A., Glaser K.B., Guo J., Li J., Marcotte P.A., Moskey M.D., Pease L.J., Stewart K.D., Yates M., Davidsen S.K., and Michaelides M.R. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorg. Med. Chem. Lett. 16 (2006) 4326-4330
20. Miyazaki Y., Matsunaga S., Tang J., Maeda Y., Nakano M., Philippe R.J., Shibahara M., Liu W., Sato H., Wang L., and Nolte R.T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 2203-2207
21. Becknell N.C., Zulli A.L., Angeles T.S., Yang S., Albom M.S., Aimone L.D., Robinson C., Chang H., and Hudkins R.L. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a] pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 5368-5372
22. Vadivelan S., Sinha B.N., Irudayam S.J., and Jagarlapudi S.A.R.P. Virtual screening studies to design potent CDK2-Cyclin A inhibitors. J. Chem. Inf. Model 47 (2007) 1526-1535
23. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
24. Okram B., Nagle A., Adrián F.J., Lee C., Ren P., Wang X., Sim T., Xie Y., Wang X., Xia G., Spraggon G., Warmuth M., Liu Y., and Gray N.S. A general strategy for creating "Inactive-Conformation" Abl inhibitors. Chem. Biol. 13 (2006) 779-786
25. Yu H., Wang Z., Zhang L., Zhang J., and Huang Q. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Chem. Biol. Drug Des. 69 (2007) 204-211
26. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
27. Smellie A., Teig S.L., and Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 16 (1995) 171-187
28. Yu H., Wang Z., Zhang L., and Huang Q. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2126-2133
29. Du L.P., Li M., Tsai K., You Q., and Xia L. Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification. Biochem. Biophys. Res. Commun. 332 (2005) 667-687